Lightnews — Scholar-powered news

OncLive @onclive.bsky.social · 3h

Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer @ucsfcancer.bsky.social #pcsm www.onclive.com/view/tarlata...

Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer | OncLive

DeLLpro-300 data provide preliminary evidence for the safety and activity of tarlatamab in DLL3-positive neuroendocrine prostate cancer.

www.onclive.com

OncLive @onclive.bsky.social · 3h

Olaparib Withstands the Test of Time With Long-Term Data Supporting Its Role in Ovarian Cancer Treatment @clevelandclinic.bsky.social #oncology #gyncsm www.onclive.com/view/olapari...

Olaparib Withstands the Test of Time With Long-Term Data Supporting Its Role in Ovarian Cancer Treatment | OncLive

Meta: Kevin Elias, MD, discusses the role of olaparib in the management of ovarian cancer.

www.onclive.com

OncLive @onclive.bsky.social · 6h

It's officially @myesmo.bsky.social week. With #ESMO25 just a few days away, catch up on OncLive's extensive tumor-specific previews, highlighting the top abstracts and data to watch throughout the meeting www.onclive.com/view/countdo...

Countdown to ESMO 2025: Catch Up on OncLive’s Extensive Tumor-Specific Previews | OncLive

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.

www.onclive.com

OncLive @onclive.bsky.social · 7h

CELMoDs Could Augment T-Cell Redirection Therapies for Prolonged Remission in R/R Myeloma @myeloma-society.bsky.social #mmsm #hematology
www.onclive.com/view/celmods...

CELMoDs Could Augment T-Cell Redirection Therapies for Prolonged Remission in R/R Myeloma | OncLive

Joshua Richter, MD, discusses the use of next-generation CELMoDs to boost T-cell responses with bispecific antibodies or CAR T-cell therapy in myeloma.

www.onclive.com

1

OncLive @onclive.bsky.social · 7h

Roswell Park Joins Other Leading Cancer Centers in Reinforcing Importance of HPV Vaccination to Prevent Cancer @roswellpark.bsky.social #oncology
www.onclive.com/view/roswell...

Roswell Park Joins Other Leading Cancer Centers in Reinforcing Importance of HPV Vaccination to Prevent Cancer | OncLive

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

www.onclive.com

OncLive @onclive.bsky.social · 8h

Ficerafusp Alfa Earns @fda.gov Breakthrough Therapy Designation for HPV-Negative, Recurrent/Metastatic HNSCC #oncology www.onclive.com/view/ficeraf...

Ficerafusp Alfa Earns FDA Breakthrough Therapy Designation for HPV-Negative, Recurrent/Metastatic HNSCC | OncLive

The FDA granted breakthrough therapy designation to ficerafusp alfa plus pembrolizumab for metastatic/recurrent head and neck squamous cell carcinoma.

www.onclive.com

OncLive @onclive.bsky.social · 9h

FDA Grants Breakthrough Therapy Designation to Sonrotoclax for R/R Mantle Cell Lymphoma #lymsm #oncology www.onclive.com/view/fda-gra...

FDA Grants Breakthrough Therapy Designation to Sonrotoclax for R/R Mantle Cell Lymphoma | OncLive

The FDA granted breakthrough therapy designation to sonrotoclax for relapsed/refractory mantle cell lymphoma.

www.onclive.com

OncLive @onclive.bsky.social · 23h

It's time for the #FiveUnder5 🕓, your go-to roundup of the top 5 #oncology videos of the week. @washumedicine.bsky.social @akritigjain.bsky.social @clevelandclinic.bsky.social @cityofhope.bsky.social @harvardmed.bsky.social

Watch the clips: 📽️: www.onclive.com/view/five-un...

#bcsm #mmsm

1 2

OncLive @onclive.bsky.social · 23h

Subcutaneous Pembrolizumab Shows Possibility of Providing Effective and Convenient Treatment in Oncology #oncology www.onclive.com/view/subcuta...

Subcutaneous Pembrolizumab Shows Possibility of Providing Effective and Convenient Treatment in Oncology | OncLive

J. Thaddeus Beck, MD, FACP, discusses the FDA approval of subcutaneous pembrolizumab in solid tumors.

www.onclive.com

OncLive @onclive.bsky.social · 2d

It's time for the #OncFive 5⃣, where we bring you the top 5 stories of the week in the world of #oncology.

Learn more about the items on the list: www.onclive.com/view/the-onc...

OncLive @onclive.bsky.social · 3d

#RCC Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 #oncology

Read the full breakdown! ⬇️

www.onclive.com/view/rcc-mon...

RCC Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 | OncLive

Check out this September recap of OncLive’s coverage of the top news and expert insights renal cell carcinoma.

www.onclive.com

OncLive @onclive.bsky.social · 3d

OST-HER2 Displays Potential OS Benefit in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma #sarcoma #oncology www.onclive.com/view/ost-her...

OST-HER2 Displays Potential OS Benefit in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | OncLive

OST-HER2 produced a potential overall survival benefit at 2 years in recurrent, fully resected, pulmonary metastatic osteosarcoma.

www.onclive.com

OncLive @onclive.bsky.social · 4d

Fruquintinib Represents Viable Later-Line Option for mCRC As Access Expands for Patients @mdanderson.bsky.social #oncology #crc #colorectalcancer
www.onclive.com/view/fruquin...

Fruquintinib Represents Viable Later-Line Option for mCRC As Access Expands for Patients | OncLive

Kanwal P.S. Raghav, MBBS, MD, discusses the role of fruquintinib for the treatment of patients with later-line colorectal cancer.

www.onclive.com

OncLive @onclive.bsky.social · 4d

#MPN Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 #oncology #hematology

Read the full article ⬇️
www.onclive.com/view/mpn-mon...

MPN Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 | OncLive

Check out this September recap of OncLive’s coverage of the top news and expert insights in myeloproliferative neoplasms.

www.onclive.com

OncLive @onclive.bsky.social · 4d

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed #Myeloma #oncology

www.onclive.com/view/daratum...

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma | OncLive

Daratumumab plus lenalidomide, with reduced exposure to dexamethasone, led to a PFS improvement in frail, newly diagnosed multiple myeloma.

www.onclive.com

1

OncLive @onclive.bsky.social · 4d

ONO-4578 Plus Nivolumab/Chemo Improves PFS in HER2– Advanced Gastric Cancer #stomachcancer #oncology www.onclive.com/view/ono-457...

ONO-4578 Plus Nivolumab/Chemo Improves PFS in HER2– Advanced Gastric Cancer | OncLive

ONO-4578 plus nivolumab and chemotherapy improved PFS in HER2-negative advanced gastric cancer.

www.onclive.com

OncLive @onclive.bsky.social · 4d

The FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue #Sarcoma. #oncology

www.onclive.com/view/fda-gra...

FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue Sarcoma | OncLive

The FDA granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.

www.onclive.com

OncLive @onclive.bsky.social · 4d

GI oncology experts share insights on the most anticipated abstracts upcoming at the #ESMO25 Congress. @mdanderson.bsky.social @mayocliniccancer.bsky.social @clevelandclinic.bsky.social @myesmo.bsky.social #oncology

Sign up to read their full insights! ⬇️
www.onclive.com/view/esmo-20...

1

OncLive @onclive.bsky.social · 4d

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma @bloodadvances.bsky.social #lymsm #hematology #oncology
www.onclive.com/view/poor-re...

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma | OncLive

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

www.onclive.com

OncLive @onclive.bsky.social · 4d

Eribulin Plus Pyrotinib Displays Efficacy in Trastuzumab-Resistant HER2+ #BreastCancer. #BCAM #BreastCancerAwarenessMonth #oncology

www.onclive.com/view/eribuli...

Eribulin Plus Pyrotinib Displays Efficacy in Trastuzumab-Resistant HER2+ Breast Cancer | OncLive

Eribulin with pyrotinib was safe and active in patients with HER2-positive advanced breast cancer who were resistant to treatment with trastuzumab.

www.onclive.com

1

OncLive @onclive.bsky.social · 5d

Urothelial Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 #oncology #urothelialcancer #urology
www.onclive.com/view/urothel...

OncLive @onclive.bsky.social · 5d

BREAKING 🚨: @fda.gov Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell Carcinoma #cscc #oncology

Read more: onclive.com/view/fda-app...

OncLive @onclive.bsky.social · 5d

FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma
#oncology #lcsm #mesothelioma
www.onclive.com/view/fda-gra...

FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma | OncLive

VT3989 has received fast track designation from the FDA for unresectable malignant nonpleural or pleural mesothelioma after progression on prior therapy.

www.onclive.com

OncLive @onclive.bsky.social · 5d

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy @fda.gov #melsm #oncology
www.onclive.com/view/wtx-124...

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy | OncLive

WTX-124 has received fast track designation from the FDA for locally advanced or metastatic cutaneous melanoma after standard-of-care immunotherapy.

www.onclive.com

OncLive @onclive.bsky.social · 5d

FDA Issues CRL for Dasatinib in Chronic Myeloid #Leukemia #oncology

www.onclive.com/view/fda-app...

FDA Issues CRL for Dasatinib in Chronic Myeloid Leukemia | OncLive

The FDA has approved dasatinib, a next-generation formulation of a protein kinase inhibitor, for the treatment of patients with chronic myeloid leukemia.

www.onclive.com